Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Tirzepatide vs placebo was associated with reduced body weight and risk for progression to type 2 diabetes across 3 years. Tirzepatide significantly reduces body weight and prevents progression to ...

Weight-loss injection Mounjaro, also known as tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this year, but many eligible patients will have to wait.

IT may be of some interest at the present moment to give a brief summary of certain comparative experiments undertaken with nitro-glycerine and gun-cotton, with a view to ascertain their ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost ...

Eli Lilly, a leading US pharmaceutical company, is gearing up to launch its groundbreaking diabetes and obesity medication, Tirzepatide—commercially known as Mounjaro—in India by 2025.

If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.

On Thursday, Dec. 19, the U.S. Food and Drug Administration announced in a statement that after two years of being in shortage, tirzepatide — the active ingredient in Zepbound and its counterpar ...

On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug is to be ...

The US FDA has approved the anti-diabetic drug Zepbound (Tirzepatide) for managing obstructive sleep apnea (OSA) in obese adults. Eli Lilly plans to launch the drug in India by 2025, pending ...